The global pancreatic cancer market will be valued at around USD 2,125.57 Million in 2023. The market of Pancreatic Cancer is projected to accelerate at a CAGR of 13.5% to top USD 7,541.09 Million by 2033.
Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | USD 1,872.75 Million |
| Expected Market Value (2023) | USD 2,125.57 Million |
| Projected Forecast Value (2033) | USD 7,541.09 Million |
| Global Growth Rate (2023 to 2033) | 13.5% CAGR |
| Expected Market Share of the USA Market (2033) | 53% |
| Anticipated Market Value of Europe (2023 to 2033) | 31% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period.
The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.
Owing to the lack of therapeutic procedures for early diagnosis, the pancreatic cancer market is expanding in developed nations
The American Society of Clinical Oncology predicts that 62,210 adults in the USA will be diagnosed with pancreatic cancer in 2022. The high prevalence of pancreatic cancer, which causes germline mutations, is also predicted to boost overall growth.
Besides that, the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to the body's healthy peripheral cells. The industry is being influenced by the increasing prevalence of pancreatic cancer and the requirement for targeted therapy.
NCI-funded research projects to empower the market to grow
The National Cancer Institute has sponsored several research programs dedicated to developing treatments and medications for pancreatic cancer. The Pancreatic Cancer Cohort Consortium, Pancreatic Cancer Cancer Detection Consortium (PCDC), Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC), Pancreatic Cancer Microenvironment Network (PaCMEN), RAS Initiative, Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), and others are instances of financed projects.
These programs each have their mission and targets, and they each seek to find novel solutions to the ailment. The Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), for instance, is an intervention designed to quickly implement principal scientific discoveries into medical settings. The Pancreatic SPORE grants promote novel and diverse methods of prevention and treatment.
Principal Consultant
rising costs of drug development and treatment, along with strict regulatory guidelines to constrain market growth
The elevated cost of drug advancement and treatment may stifle future growth. During the projected timeframe, the market will also face obstacles from stringent government laws and regulations. Inventions and comprehensive authorization methods can assist in overcoming these challenges and propelling the global pancreatic cancer market forward.
In 2021, the North American pancreatic cancer market dominated the global market. This is because pancreatic cancer is more prevalent in North American countries, with the USA having the most cancer victims globally. As a consequence, North America possessed the leading revenue proportion in the pancreatic cancer treatment market in 2021. It is primarily owing to the upgraded healthcare system, widespread utilization of pancreatic treatment procedures, and a huge target citizenry. Furthermore, the increasing prevalence of pancreatic cancer is driving up requirements for treatment options.
The Asia-Pacific pancreatic cancer market is expected to be the most rapidly sprouting in the globe. Asia Pacific, as a result, hand, is projected to expand the fastest during the projected timeline. The existence of well-established clinics and critical care centers, as well as a massive population suffering from pancreatic cancer, would help the industry develop in the Asia Pacific region. Furthermore, with the increasing number of pancreatic cancer cases in Asia Pacific, pancreatic cancer diagnosis and treatment must abide by the same protocol as in Western nations.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The rapid rise of pancreatic cancer patients and, increased investment in healthcare infrastructure propel the market
In North America, the USA of America leads the pancreatic cancer market. Based on the American Cancer Society's National Survey, approximately 3% of cancers in the USA were pancreatic by 2021. Moreover, pancreatic cancers account for 9% of all cancer deaths. The rising number of pancreatic cancer patients is accompanied by higher investment in medical infrastructure.
The simplification of regulatory approval processes has resulted in the safe and prompt approval of clinical drugs and treatments in the USA, contributing to the rising demand for pancreatic cancer treatment options in the country.
Surging tobacco consumption levels will propel the market forward
Germany had the highest number of cases reported of pancreatic cancer in Europe in 2021, with 21,859 cases. Rising tobacco consumption rates and a boost in cigarette smokers are expected to boost the expansion of the pancreatic cancer market.
Rising cancer prevalence, increased alcohol consumption, rising obesity rates, and increasing acceptance of various treatment options available are all forecasting overall growth in this country.
Country-wise Forecast CAGRs for the Pancreatic Cancer Industry
| China | 12% |
|---|---|
| USA | 13.7% |
| Australia | 10% |
| France | 11% |
The hospital's segment is dominant owing to the modern infrastructure
Based on end-user, the Hospital segment is the largest profit segment in the global pancreatic cancer therapeutics market, and this trend is expected to persist in the forecast years. The hospital segment is dominant owing to the quick influx of patients admitted to hospitals due to competent medical practitioners and the accessibility of multiple systems. In addition, hospitals have the decent infrastructure and a wide network, which is cruising market growth. The hospital segment accounted for a 48% share of the market in 2022.
Surgery and radiology segments are expected to lead the industry
Because of the incidence of these methodologies, treatment-type segments such as surgery and radiology are likely to dominate the market throughout the forecast period.
The prominence of targeted drugs and unique biologic therapeutics can also be credited to this segment's supremacy. Furthermore, personalized treatment systems are assisting in the segment's advancement.
Biosense was established in 2008. Biosense is a medical engineering and development company that produces ground-breaking diagnostics. Rexahn announced a contract with BioSense in April 2019 to commercialize its pancreatic cancer treatment in Greater China.
ElmediX was established in 2015 as a spin-off of the University of Antwerp with a single objective in mind: to produce a disruptive solution for (pancreatic) cancer and other life-threatening ailments. They produce oncothermia-based treatments for pancreatic cancer that minimize the likelihood of toxicity to healthy tissue.
Key players in the pancreatic cancer market are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 2,125.57 Million |
| Projected Forecast Value (2033) | USD 7,541.09 Million |
| Global Growth Rate (2023 to 2033) | 13.5% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment Type, Cancer Type, End Use, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Pfizer Inc.; Novartis AG; Eli Lily and Company; Bristol Myers Squibb Company; Zydus Cadila; Myriad Genetics Inc.; F-Hoffmann-La Roche Ltd.; PharmaCyte Biotech Inc.; Teva Pharmaceutical Industries Ltd. |
| Customization | Available Upon Request |
As of 2022, the Pancreatic Cancer market was worth USD 73.75 Million.
Fact.MR foresees Pancreatic Cancer demand to reach USD 2125.57 Million in 2023.
From 2023 to 2033, Fact.MR expects Pancreatic Cancer revenue to flourish at a 13.5% CAGR.
In 2033, Pancreatic Cancer market worth is poised to reach USD 7541.09 Million.
North American regional market is expected to rise 1.4X by 2033.
The USA is expected to possess a 35% market share for Pancreatic Cancer in 2033.
1. Executive Summary | Pancreatic Cancer Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Chemotherapy 5.2. Immunotherapy 5.3. Hormone Therapy 5.4. Surgery 5.5. Radiation Therapy 5.6. Targeted Drug Therapy 5.7. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals 7.2. Clinics 7.3. Diagnostic Laboratories 7.4. Research Institutes 7.5. Research Laboratories 7.6. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Pfizer Inc. 16.2. Novartis AG 16.3. Eli Lilly and Company 16.4. Bristol Myers Squibb Company 16.5. Zydus Cadila 16.6. AstraZeneca PLC 16.7. Myriad Genetics Inc. 16.8. F Hoffmann-La Roche Ltd. 16.9. PharmaCyte Biotech Inc. 16.10. Teva Pharmaceutical Industries Ltd. 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Pancreatic Cancer Market
